Loading
A phase 1/2 trial of Belantamab mafodotin, Nirogacestat, Lenalidomide in multiple myeloma, run by GlaxoSmithKline, active and no longer recruiting.
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM is a phase 1/2 interventional study registered as NCT07150091 by GlaxoSmithKline, with 20 participants enrolled, started 2022-07-19 and due to reach its primary completion in 2025-04-17. Interventions recorded: Belantamab mafodotin, Nirogacestat, Lenalidomide, Dexamethasone. Conditions listed: Multiple Myeloma. Results were posted on ClinicalTrials.gov in 2026; the figures recorded here are the registry's, not a publication's.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
20 enrolled.
Figures from the ClinicalTrials.gov results section (first posted 2026-06-16), not from a publication
Source95% CI 12.2 to 73.8; Figures from the ClinicalTrials.gov results section (first posted 2026-06-16), not from a publication · 95% CI 34.8 to 93.3
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| DE Phase: Number of Participants With Dose Limiting Toxicities (DLTs)primary | 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Lenalidomide + Dexamethasone | 5 | 1 participants | - | - | link |
| 1.0 mg/kg Belantamab Mafodotin + Nirogacestat + Lenalidomide + Dexamethasone | 5 | 2 participants | ||||
| DE Phase: Overall Response Rate (ORR) | 0.5 Milligram/Kilogram (mg/kg) Belantamab Mafodotin + Nirogacestat + Lenalidomide + Dexamethasone | 10 | 40% | - | - | link |
| 1.0 mg/kg Belantamab Mafodotin + Nirogacestat + Lenalidomide + Dexamethasone | 10 | 70% |
Shares Gamma-secretase inhibitors, Nirogacestat, Belantamab mafodotin, Antiemetics for chemotherapy-induced nausea and vomiting.
Shares Gamma-secretase inhibitors, Nirogacestat, Belantamab mafodotin, GSK.
Shares Belantamab mafodotin, Antiemetics for chemotherapy-induced nausea and vomiting, GSK, Dexamethasone.
Shares Belantamab mafodotin, Antiemetics for chemotherapy-induced nausea and vomiting, GSK, Lenalidomide.
Shares Belantamab mafodotin, Antiemetics for chemotherapy-induced nausea and vomiting, GSK, Dexamethasone.
Shares Belantamab mafodotin, Antiemetics for chemotherapy-induced nausea and vomiting, GSK, Dexamethasone.
Shares Nirogacestat, Belantamab mafodotin, GSK, Lenalidomide.
Shares Belantamab mafodotin, GSK, Relapsed or refractory multiple myeloma, Multiple myeloma.